Wolf-K Hofmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wolf-K Hofmann has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Dieter Hoelzer
Department of Hematology and Oncology, Hospital of J.W. Goethe University, Frankfurt/Main, Germany
2 shared publications- Eckhard Thiel
Department of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
2 shared publications H. Phillip Koeffler
Division of Hematology and Oncology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, California 90048
2 shared publicationsMartina Komor
Department of Hematology and Oncology, Hospital of J.W. Goethe University, Frankfurt/Main, Germany
2 shared publications- Anne Letsch
Med. Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
1 shared publication Claudia Baldus
1 shared publication
Latest Publications
- 31 March 2009
- Published by Elsevier in Leukemia Research
- Vol. 33 (3) , 434-442
Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms
- 31 March 2009
- Published by Elsevier in Leukemia Research
- Vol. 33 (3) , 434-442
Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms
- Open Access
- 15 January 2009
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 7 (1) , 7
High correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia
- 15 January 2009
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 7 (1) , 7
Open AccessHigh correlation of the proteome patterns in bone marrow and peripheral blood blast cells in patients with acute myeloid leukemia
- 1 November 2006
- Published by Elsevier in Leukemia Research
- Vol. 30 (11) , 1347-1353
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome
- 1 November 2006
- Published by Elsevier in Leukemia Research
- Vol. 30 (11) , 1347-1353
Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome
- Open Access
- 1 September 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 23 (8) , 1154-1169
Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage‐Specific Differentiation
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.
- 1 September 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 23 (8) , 1154-1169
Open AccessTranscriptional Profiling of Human Hematopoiesis During In Vitro Lineage‐Specific Differentiation
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.
- 1 February 2005
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 56 (1) , 1-16
Myelodysplastic Syndrome
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS.
- 1 February 2005
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 56 (1) , 1-16
Myelodysplastic Syndrome
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS.
- 1 December 2004
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 5 (12) , 2451-2458
Therapeutic spectrum in the treatment of myelodysplastic syndromes
During the last 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndromes (MDS). It is a clonal disorder, characterised by ineffective haematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukaemias. Risk-adapted treatment strategies were established, due to the high median age (60 - 75 years) of the MDS patients and the individual history of the disease (i.e. number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the 'typical' MDS patient, who is > 60 years of age. Therapy with erythropoietin and granulocyte colony-stimulating factor has improved the quality of life of selected patients. The development of target-specific therapies, including antibodies and small molecules directed against specific molecular alterations in MDS, with minimal adverse effects, is the hope for the future. Furthermore, the innovative use of immunomodulatory agents and the optimising of cytotoxic treatment should continue to help in the treatment of MDS.
- 1 December 2004
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 5 (12) , 2451-2458
Therapeutic spectrum in the treatment of myelodysplastic syndromes
During the last 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndromes (MDS). It is a clonal disorder, characterised by ineffective haematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukaemias. Risk-adapted treatment strategies were established, due to the high median age (60 - 75 years) of the MDS patients and the individual history of the disease (i.e. number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the 'typical' MDS patient, who is > 60 years of age. Therapy with erythropoietin and granulocyte colony-stimulating factor has improved the quality of life of selected patients. The development of target-specific therapies, including antibodies and small molecules directed against specific molecular alterations in MDS, with minimal adverse effects, is the hope for the future. Furthermore, the innovative use of immunomodulatory agents and the optimising of cytotoxic treatment should continue to help in the treatment of MDS.
- 1 April 2002
- Vol. 8 (4) , 939-41
Differentiation therapy for myelodysplastic syndrome.
- 15 March 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (6) , 2032-2036
Expression of C/EBPβ from the C/ebpα gene locus is sufficient for normal hematopoiesis in vivo
CCAAT/enhancer-binding proteins (C/EBPs) are critical transcriptional regulators of differentiation of hematopoietic cells. Previous studies have shown that targeted disruption of theC/ebpα gene results in a lack of granulocytic differentiation with an arrest at the stage of immature myeloblasts. By using a gene replacement strategy in which C/EBPβ was expressed from the C/ebpα gene locus of C/EBPα-null mice, we have evaluated the ability of C/EBPβ to function for C/EBPα in directing differentiation along the granulocytic pathway. We show that the morphology and the differential cell counts of the bone marrow and peripheral blood cells from C/EBPβ knockin mice are indistinguishable from those of their wild-type littermates, indicating that hematopoiesis occurs normally in these animals. Additionally, we analyzed expression of 21 myeloid-specific genes, including markers for distinct stages of granulocytic differentiation, and found no significant differences in their levels of expression in the bone marrow of C/EBPβ knockin and wild-type mice. These results imply that C/EBPβ can substitute for C/EBPα during hematopoiesis when expressed from the C/ebpα gene locus.
- 15 March 2002
- Published by American Society of Hematology in Blood
- Vol. 99 (6) , 2032-2036
Expression of C/EBPβ from the C/ebpα gene locus is sufficient for normal hematopoiesis in vivo
CCAAT/enhancer-binding proteins (C/EBPs) are critical transcriptional regulators of differentiation of hematopoietic cells. Previous studies have shown that targeted disruption of theC/ebpα gene results in a lack of granulocytic differentiation with an arrest at the stage of immature myeloblasts. By using a gene replacement strategy in which C/EBPβ was expressed from the C/ebpα gene locus of C/EBPα-null mice, we have evaluated the ability of C/EBPβ to function for C/EBPα in directing differentiation along the granulocytic pathway. We show that the morphology and the differential cell counts of the bone marrow and peripheral blood cells from C/EBPβ knockin mice are indistinguishable from those of their wild-type littermates, indicating that hematopoiesis occurs normally in these animals. Additionally, we analyzed expression of 21 myeloid-specific genes, including markers for distinct stages of granulocytic differentiation, and found no significant differences in their levels of expression in the bone marrow of C/EBPβ knockin and wild-type mice. These results imply that C/EBPβ can substitute for C/EBPα during hematopoiesis when expressed from the C/ebpα gene locus.